Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies (Euronext: DBV – Nasdaq: DBVT) has released its Half-Year report detailing its liquidity contract with ODDO BHF as of June 30, 2021. The liquidity account held 77,875 shares and €480,481.63 in assets, compared to 24,313 shares and €682,454.94 at the contract's inception in July 2018. During the second half of 2020, a total of 1,105 purchases and 1,146 sales were executed, with 461,457 shares bought for €4.3 million and 495,884 shares sold for €4.5 million.
- Increase in liquidity account holdings: 77,875 shares compared to 24,313 at contract initiation.
- Total assets in liquidity account increased to €480,481.63 from €682,454.94 in July 2018.
- Decrease in total liquidity account value from €682,454.94 to €480,481.63 over the period.
- Selling volume exceeded buying volume, indicating potential liquidity challenges.
AMF REGULATED INFORMATION
Montrouge, France, August 6, 2021
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.
As of June 30, 2021, the following assets appeared on the liquidity account:
- 77,875 DBV Technologies shares;
€ 480,481.63 .
Upon signing the liquidity contract in July 2018, the following resources appeared on the liquidity account:
- 24,313 DBV Technologies ordinary shares;
€ 682,454.94 .
Number of transactions executed during the second half-year of 2020:
- Purchase: 1,105
- Sale: 1,146
Over the same period, the volumes traded represented:
- 461,457 DBV Technologies ordinary shares purchased for
€4,297,042.80 - 495,884 DBV Technologies ordinary shares sold for
€4,548,434.80
About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Summit, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com
Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com
Attachment
FAQ
What is the liquidity contract update for DBVT as of June 30, 2021?
How many shares did DBVT purchase and sell in 2020?
What was the total value of shares purchased and sold by DBVT?
